Leerink Partnrs Issues Optimistic Forecast for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a research report issued on Wednesday, June 25th. Leerink Partnrs analyst D. Risinger now forecasts that the pharmaceutical company will earn $4.29 per share for the quarter, up from their prior estimate of $4.28. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period in the prior year, the business earned $4.76 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis.

VRTX has been the subject of a number of other reports. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Erste Group Bank lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 23rd. Leerink Partners reiterated a “market perform” rating and issued a $503.00 price objective (down from $550.00) on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. increased their price objective on Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Monday. Fourteen research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $513.14.

Vertex Pharmaceuticals Trading Down 0.5%

VRTX stock opened at $443.40 on Thursday. The business has a fifty day moving average price of $455.45 and a 200 day moving average price of $459.02. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The stock has a market capitalization of $113.87 billion, a price-to-earnings ratio of -113.11 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.65 and a quick ratio of 2.29.

Hedge Funds Weigh In On Vertex Pharmaceuticals

Large investors have recently bought and sold shares of the company. AG2R LA Mondiale Gestion D Actifs acquired a new stake in Vertex Pharmaceuticals during the first quarter worth approximately $4,244,000. Voya Investment Management LLC grew its stake in Vertex Pharmaceuticals by 18.4% during the first quarter. Voya Investment Management LLC now owns 827,138 shares of the pharmaceutical company’s stock worth $400,719,000 after purchasing an additional 128,432 shares during the period. Howe & Rusling Inc. grew its stake in Vertex Pharmaceuticals by 2.6% during the first quarter. Howe & Rusling Inc. now owns 9,126 shares of the pharmaceutical company’s stock worth $4,424,000 after purchasing an additional 232 shares during the period. First Hawaiian Bank grew its stake in Vertex Pharmaceuticals by 9.3% during the first quarter. First Hawaiian Bank now owns 5,404 shares of the pharmaceutical company’s stock worth $2,620,000 after purchasing an additional 462 shares during the period. Finally, Modern Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the first quarter worth approximately $458,000. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.